The hypothesis that VGF and its derived neuropeptides may play a role in the context of different neurodegenerative diseases is supported by the evidence of altered levels of specific proVGF-derived fragments in CSF from dementia with Lewy bodies (DLB) [63], Parkinson’s disease (PD) [65], AD [66], multiple sclerosis [67], and ALS [68,69,70]. This evidence concerns the gene VGF and Parkinson disease.